All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 1 reads as filed from the record and 8 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2023-09-12.
From the record
abrdn Life Sciences Investors' filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2023-09-12) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
SI estimate 5.1/10, confidence 15 of 100 (universe median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: abrdn Life Sciences Investors's track record is put at 5.1 of 10 with a confidence of 15 of 100, because fewer than three filed years of revenue on file, and its family carries too few readings to lean on, so the desk assumes the typical reading over all 4561 companies with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
How has it treated the people who own it?
SI estimate 5.5/10, confidence 15 of 100 (universe median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: abrdn Life Sciences Investors's shareholder treatment is put at 5.5 of 10 with a confidence of 15 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, and its family carries too few readings to lean on, so the desk assumes the typical reading over all 4090 companies with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
SI estimate 5.0/10, confidence 15 of 100 (universe median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: abrdn Life Sciences Investors's financial health is put at 5.0 of 10 with a confidence of 15 of 100, because no balance sheet on file, and its family carries too few readings to lean on, so the desk assumes the typical reading over all 5056 companies with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
How strong is its position in its industry?
SI estimate 5.2/10, confidence 15 of 100 (universe median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: abrdn Life Sciences Investors's industry position is put at 5.2 of 10 with a confidence of 15 of 100, because no filed revenue on file, and its family carries too few readings to lean on, so the desk assumes the typical reading over all 4643 companies with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are the people in charge doing?
SI estimate 2.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: abrdn Life Sciences Investors's leadership is put at 2.5 of 10 with a confidence of 35 of 100, because read from one part only, the median years the people in charge have been filing, which ranks in the bottom 25% of 4 in its family; it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
SI estimate 4.9/10, confidence 15 of 100 (universe median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: abrdn Life Sciences Investors's room to expand is put at 4.9 of 10 with a confidence of 15 of 100, because the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue, and its family carries too few readings to lean on, so the desk assumes the typical reading over all 4460 companies with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What could actually drive growth from here?
SI estimate 5.0/10, confidence 15 of 100 (universe median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: abrdn Life Sciences Investors's growth drivers is put at 5.0 of 10 with a confidence of 15 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, and its family carries too few readings to lean on, so the desk assumes the typical reading over all 4521 companies with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
Did its newest year beat what its own record pointed to?
SI estimate 5.1/10, confidence 15 of 100 (universe median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: abrdn Life Sciences Investors's expectations vs reality is put at 5.1 of 10 with a confidence of 15 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, and its family carries too few readings to lean on, so the desk assumes the typical reading over all 4126 companies with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made